Company Overview of Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc., a biopharmaceutical company, develops production and purification procedures for proteins that attack and destroy pathologic cells. It develops hI-con1, a recombinant protein that triggers immune cell-mediated killing of TF-expressing uterine serous papillary adenocarcinoma and clear cell ovarian cancer cells. The company was incorporated in 2002 and is based in Atlanta, Georgia.
127 Peachtree Street, N.E.
Atlanta, GA 30303
Founded in 2002
Key Executives for Iconic Therapeutics, Inc.
Co-Founder, President, Chief Financial Officer and Director
Chief Scientist and Scientific Advisor
Compensation as of Fiscal Year 2014.
Iconic Therapeutics, Inc. Key Developments
Iconic Therapeutics, Inc. Appoints K. Peter Hirth as Director and Senior Scientific Advisor
May 12 15
Iconic Therapeutics, Inc. announced that K. Peter Hirth, PhD, co-founder and formerly Chief Executive Officer of Plexxikon, Inc., has been named a Director of the company and will work closely with Iconic's leadership team as a Senior Scientific Advisor. Dr. Hirth has over 30 years of biotechnology and pharmaceutical discovery and development experience and currently serves as a Board member of Spinomix, KineMed, Kolltan Pharmaceuticals, and Afferent Pharmaceuticals. From 2001 to 2013 at Plexxikon, Dr. Hirth built a novel, structure-guided drug discovery platform, which brought several new chemical entities into the clinic, including Zelboraf, an FDA-approved therapy for metastatic melanoma together with a companion diagnostic. Prior to Sugen, he was Vice President of Research at Boehringer Mannheim where he successfully led the company's erythropoietin program to approval in 1989. Dr. Hirth was a research scientist with the Max Planck Institute. He completed his post-doctoral work at the University of California, San Diego and received his PhD in molecular genetics from Heidelberg University, Germany.
Iconic Therapeutics, Inc. Announces Management Appointments
Apr 16 14
Iconic Therapeutics, Inc. announced that MPM partner William Greene, MD, has joined the company as Chief Executive Officer. Additionally, MPM Managing Director Todd Foley, H.I.G. Managing Director Bruce Robertson, PhD, and Lundbeckfond Ventures Senior Partner Johan Kordel, PhD, have joined the Board of Directors. Prior to joining Iconic Therapeutics, Dr. Greene was a Managing Director at MPM Capital. Previously, he was a Senior Clinical Scientist at Genentech where he led the early clinical development of Lucentis for AMD.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|